Clinical Trial Update: A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study) [Phase 2, Phase 3]

View source ↗

Summary

A multicenter Phase 2/Phase 3 trial evaluating the NSAID naproxen and the COX-2 inhibitor rofecoxib in Alzheimer’s disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Naprosyn (naproxen)
• Vioxx (rofecoxib) (rofecoxib)

Snippet

Sponsor: National Institute on Aging (NIA) | Conditions: Alzheimer Disease | Phase 2, Phase 3 | Status: COMPLETED